---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-045362"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:29:45.679611+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PAVmed reports Q3 GAAP net income $64.3M driven by deconsolidation; Lucid EsoGuard revenue record $1.2M

## Summary
- Lucid Q3 EsoGuard revenue $1.2M, a record; 2,787 commercial tests; October single-month record >1,400 tests.
- GAAP net income $64.3M ($1.44 diluted EPS) largely due to Lucid deconsolidation; non-GAAP adjusted loss $5.4M ($0.54/share).
- Cash and equivalents $0.8M as of Sept 30, 2024, down from $19.6M at Dec 31, 2023.
- PAVmed deconsolidated Lucid on Sept 10; reached agreement to exchange $25M convertible debt for preferred equity to regain Nasdaq compliance; extension to Jan 31, 2025.
- Veris completed pilot with Ohio State's James Cancer Hospital and awarded $1.8M NIH grant.

## SEC filing metadata
- accession: 0001493152-24-045362
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315224045362/0001493152-24-045362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315224045362/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-045362
- JSON: https://secwatch.observer/filing/0001493152-24-045362.json
- Plain text: https://secwatch.observer/filing/0001493152-24-045362.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.